

1 **Burden of Liver Cancer in China from 1990 to 2019 and projections to 2044:**
2 **Findings from the Global Burden of Disease Study**

3 *Jianglong Han^{a*}, Chao Chen^{b*}, Tian Tang^{a*}, Wenmin Liu^a, Ruyan Chen^a, Si Li^a,*
4 *Haiyu Deng^a, Tingting Jian^a, Liang Zhao^{c#}, Zhenming Fu^{a#}*

5 *^aCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China*

6 *^bDepartment of Anorectal Surgery, the 8th Hospital of Wuhan, Wuhan, 430010, China*

7 *^cDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan,*
8 *430060, China*

9

10 **Short title: Liver cancer burden in China**

11

12 *These authors contributed equally to this paper.

13 #Correspondence to:

14 *Dr. Zhenming Fu, Cancer Center, Renmin Hospital of Wuhan University, Wuhan,*
15 *430060, China. E-mail: davidfuzming@whu.edu.cn.*

16 *Dr. Liang Zhao, Department of Gastroenterology, Renmin Hospital of Wuhan*
17 *University, Wuhan, 430060, China. E-mail: airmanzhao@whu.edu.cn*

18 Number of Tables: 2.

19 Number of Figures: 3.

20 Word count for main text: 2,861 words.

21 **Guarantor of the article:** ZF and LZ;

22 **Specific author contributions:** ZF, LZ, JH, TT and CC: conception/design. JH, CC,
23 TT, and WL: collection and/or assembly of data. JH, CC, TT, and RC: data analysis
24 and interpretation. JH, CC, RC, SL, HD and TJ: manuscript writing. JH, CC, TT, WL,
25 RC, SL, HD, TJ, and ZF: final approval of manuscript. The work reported in the paper
26 has been performed by the authors, unless clearly specified in the text.

27 **Financial support:** This study was partially supported by the National Natural
28 Science Foundation of China [grants 81773555], the funders had no role in the design
29 of the study or the interpretation of the findings.

30 **Potential competing interests:** The authors declare that the research was conducted
31 in the absence of any commercial or financial relationships that could be construed as
32 a potential conflict of interest.

33 **Abstract**

34 **Background:** China has the highest liver cancer burden in the world. Prediction and
35 comparison of the future trends of liver cancer in China and some representative areas
36 may guide further control action.

37 **Methods:** Using data from the Global Burden of Disease Study, we assessed
38 incidence, mortality, and disability-adjusted life-years of liver cancer in Mainland
39 China, with reference to representative East Asia areas (Taiwan China, Japan, and
40 Korea) and Western areas (the United Kingdom and the United States). The burden of
41 liver cancer was evaluated and predicted using NOREPRED model from 1990 to
42 2044.

43 **Results:** Overall, the liver cancer incidence (28.1 to 10.6 per 100,000) and mortality
44 (27.5 to 9.7 per 100,000) decreased from 1990 to 2015 in Mainland China, which
45 were consistent with the trends of Eastern Asia areas. However, the disease burden in
46 Mainland China were then plateaued and started to increase during 2015-2044 (10.6
47 to 14.8 per 100,000 for incidence; 9.7 to 14.02 per 100,000 for mortality), including
48 the hepatitis-related liver cancer incidence (increase from 8.6 to 11.7 per 100,000).
49 While the changing patterns of alcohol- and nonalcoholic steatohepatitis (NASH)-
50 related liver cancer incidence were found similar among Mainland China (0.93 to 1.51
51 per 100,000 for alcohol; 0.5 to 0.73 per 100,000 for NASH) and Western countries in
52 our projection.

53 **Conclusion:** The liver cancer burden in Mainland China is unexpectedly predicted to
54 increase again after decades of decline. Future efforts must be made to resolve both
55 the remaining hepatitis-related cancer burden and the changing etiologies.

56 **Keyword:** Liver cancer; Disease burden; Projection; Age-period-cohort analysis;
57 Global Burden of Disease Study.

58 **Introduction**

59 Liver cancer is the sixth most common malignancy and the third cause of cancer-
60 related death worldwide, with approximately 905,677 new cases and 830,180 deaths
61 in 2020(1). The disease burden of liver cancer has increased globally over the last few
62 decades, with the highest disease burden observed in East Asia(2, 3), especially in
63 Mainland China(1). In 2020, Mainland China had 410,038 newly diagnosed liver
64 cancer cases and 391,105 related deaths, which comprised half the global burden(1).
65 Fortunately, attributed to great public health efforts in controlling hepatitis virus
66 infection, the incidence and mortality rates of liver cancer were reported to be
67 declining in East Asia in recent studies(4, 5).

68 Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are the main risk
69 factors for liver cancer development, accounting for almost half of the cases
70 worldwide(6). Currently, HBV infection is still the leading risk factor for liver cancer
71 in China, while HCV infection is the major risk factor for liver cancer in South Korea
72 and Japan and other developed areas(7, 8). However, liver cancer is a multifactorial
73 disease(9). Other modifiable factors such as obesity and unhealthy lifestyles,
74 including alcohol consumption, intake of fatty food, and lack of exercise, also play
75 important roles in its development(10). Recently, it is reported that the high
76 prevalence of alcoholic liver disease (ALD) and nonalcoholic fatty liver disease
77 (NAFLD) or nonalcoholic steatohepatitis (NASH) in Western populations result in the
78 upward trend in liver cancer (11, 12). The heterogeneous prevalence of risk factors in
79 different regions may also lead to different disease burdens. In the past few decades,
80 great efforts have been undertaken in East Asia, including Mainland China(13), to
81 prevent hepatitis virus infection through national vaccination programs, blood supply
82 management, and management of virus carriers. Therefore, the prevalence of hepatitis
83 infection and related liver cancer burden was found to decline in this area(14-16).

84 Recently, there has been significant increase in the consumption of alcohol, refined
85 grains, and highly processed foods, while physical activity decreased with increasing
86 sedentary behaviors in Mainland China(17).As a result, the rapid emergence of
87 alcohol- and NASH-related liver cancer may offset or even surpass the likely decline
88 in the burden of hepatitis-related liver cancer in Mainland China. Therefore, we used
89 the data derived from the Global Burden of Disease (GBD) Study 2019 to examine
90 the current trends of liver cancer burden in China by specific etiologies and projected
91 the trends to 2044.

92

93 **Materials and methods**

94 **Data source**

95 The GBD study provides a standardized approach for estimating incidence, mortality,

96 and disability-adjusted life-years (DALYs), as well as DALYs by cause, age, sex, year,
97 and location, aiming to use all accessible information on disease occurrence, natural
98 history, and severity that passes a set of inclusion criteria(18). The detailed methods of
99 the GBD study (1990-2019) have been reported in previous studies(18, 19). We
100 collected annual liver cancer case data between 1990 and 2019 by sex, region
101 (Mainland China, East Asia areas: Taiwan China, Japan, and Republic of Korea;
102 Western areas: US and UK), etiology (alcohol use, HBV, HCV, and NASH), and age
103 group (from under 5 to 85+ years in 5-year intervals) from the Institute for Health
104 Metrics and Evaluation (<http://ghdx.healthdata.org/gbd-results-tool>). The data on
105 incidence, mortality, and DALYS were chosen as measures in the inquiry tools. The
106 age-standardized incidence (ASIR), mortality (ASMR), and DALY (ASDR) rates
107 were adjusted by the World Health Organization standard population distribution
108 (2000-2025) per 100,000 person-years. Patient consent was not required because the
109 study is a retrospective database research in nature, and there was no direct patient
110 contact. Institutional Review Board approval was not required according to our
111 institution policy.

112 **Statistical analysis**

113 We described the liver cancer incidence, mortality, and DALYs by 5-year age groups,
114 locations, and etiologies. Temporal trends of these variables were plotted by location
115 and etiology using the age-standardized rates. The temporal trends were divided into
116 two periods: 1990-2019 was regarded as the observed trend plotted as solid lines, and
117 2020-2044 was regarded as the predicted trend plotted as dashed lines.

118 We used a log-linear age-period-cohort model to level off exponential growth and
119 limit linear trend forecasts to observed trends (1990-2019). The NOREPRED package
120 with Power5 and Poisson APC models in R software were developed and
121 implemented in projecting trends into the future(20). We further utilized the APC
122 method to make projections of liver cancer burden up to 2044. Projections were
123 carried out in 5-year intervals through 2020-2044. Changing trends in observed
124 periods (1990-2019) were extrapolated using the power function of the NOREPRED
125 package to level off the growth, with a projection of the linear trends for the last two
126 observed 5-year periods. The projected trend was attenuated by 25% and 50% for the
127 second (2025-2029) and third (2030-2034) predicted periods, respectively, and then
128 75% for the fourth and fifth projected periods (2035-2044)(21). The predicted
129 population by age group and region from 2020 to 2044 was obtained from the United
130 Nations World Population Prospects 2019 Revisions in a 5-year period(21). R 4.1 was
131 used for analysis, including the functions available in R studio and the NORDPRED
132 package. GraphPad Prism 8 was used to visualize the results.

133

134 **Results**

135 **Incidence, mortality, and DALYs of liver cancer by region, 1990-2019**

136 Overall, the highest incidence, mortality, and DALY rates of liver cancer were
137 observed in East Asia from 1990 to 2019 (**Figure 1A, 2A, and 3A**). The highest ASIR
138 was observed in Mainland China at 28.1 per 100,000 in 1990, followed by Japan at
139 16.16 per 100,000, Taiwan China, at 12.83 per 100,000, and South Korea at 9.14 per
140 100,000. Between 1990 and 2019, continuously decreased incidences were observed
141 in Mainland China, Japan, and Taiwan China, whereas the incidence in South Korea
142 increased 184% from 1990 to 2004 and then decreased from 23.63 to 11.44 per
143 100,000 through 2019. The UK (2.01 to 4.82 per 100,000) and US (2.36 to 4.94 per
144 100,000) showed slight but continuous increases in incidence over the period.

145 Similarly, the highest ASMR and ASDR were observed in Mainland China, followed
146 by Japan, Taiwan China, and South Korea in 1990, but significant decreasing trends
147 were also observed in these areas. The figures in Mainland China decreased for more
148 than two decades from 1990 to 2015 but started to increase again in 2015. However,
149 unlike the trends of ASIR and ASDR, the temporal trends of South Korea decreased in
150 the ASMR through 2019. Slight but steady increases in ASMR and ASDR were
151 observed in the UK and US.

152 **Incidence, mortality, and DALYs of liver cancer by etiology, 1990-2019**

153 Among all four underlying etiologies, the highest disease burden was observed in
154 HBV-related liver cancer, followed by HCV, alcohol consumption, and NASH in
155 China and selected areas (**Table 1**). Overall, the highest ASIRs were observed in
156 Mainland China among HBV (18.63 per 100,000), alcohol (2.1 per 100,000), and
157 NASH-related (1.06 per 100,000) liver cancer in 1990, whereas the highest HCV-
158 related ASIR of liver cancer (10.45 per 100,000) was seen in Japan. Remarkable
159 decreases were found in the ASIRs of alcohol (-62%), HBV (-64%), HCV (-63%),
160 and NASH (-60%) related to liver cancer in Mainland China from 1990 to 2015, and
161 ASIRs have plateaued or slightly increased since 2015 (**Table 2**). In contrast, the
162 ASIR of South Korea showed a rapid increase from 1990 to 2004 among all etiology-
163 related liver cancers and then slowly decreased through 2019. Similar increasing
164 trends were observed in the US and UK for liver cancers due to alcohol and NASH,
165 whereas the ASIRs of hepatitis virus-related liver cancer plateaued in the UK and US
166 throughout the study periods. Similar trends for ASMR and ASDR were also found in
167 all regions regardless of etiology, with the highest disease burden of hepatitis virus-
168 related liver cancers in Eastern countries and consistent upward trends in alcohol and
169 NASH-related disease in Western countries.

170 **Prediction of incidence, mortality, and DALYs of liver cancer, 2020-2044**

171 Based on GBD data on liver cancer from 1990 to 2019, we further predicted the ASIR,
172 ASMR, and ASDR in the next 25 years (**Figures 1, 2, 3**). By region, Mainland China,
173 the US, and the UK showed continuous increases in incidence, mortality, and DALYs.
174 The increases in Mainland China were 44% for incidence and 42% for mortality and
175 DALYs, while the increases in incidence, mortality, and DALYs were 12.4%, 2.4%,
176 and 6.6% for the UK and 2.6%, 3.2%, and 7.5% for the US, respectively (**Table 2**). In
177 the rest of the regions, the incidence of liver cancer is predicted to decrease by 48.7%
178 for Japan, 21.5% for Taiwan China, and 25.6% for Korea from 2020 to 2044, while
179 mortality and DALYs in these areas will decline in a similar manner.

180 Universal increasing trends were observed for Mainland China for all etiological
181 factors in incidence, mortality, and DALYs from 2020 to 2044. For HBV-related liver
182 cancers, which are the predominant hepatitis virus-related liver cancers in Mainland
183 China, trends were predicted to continuously increase in incidence (from 6.86 to 9.43
184 per 100,000), mortality (6.03 to 8.59 per 100,000), and DALYs (188.89 to 272.49 per
185 100,000) from 2020 to 2044. In Western areas, the incidence of liver cancer due to
186 alcohol will increase by 6.7% for the UK and 16.1% for the US from 2020 to 2044,
187 whereas NASH-related liver cancer increases by 15.1% for the UK and 10.6% for the
188 US. However, mortality and DALYs will plateau in the UK and US over the predicted
189 periods (**Figure 2D, E and Figure 3D, E**).

190 **Discussion**

191 In this study, we demonstrated the highest incidence of liver cancer was observed in
192 Mainland China in 1990 at 28.1 per 100,000 and then declined considerably and
193 ended at 10.6 per 100,000 in 2015. Unexpectedly, for the first time, we found that the
194 liver cancer burden has started to increase again in Mainland China since 2015, unlike
195 the continuous decline in other East Asian areas. Moreover, we predicted that it will
196 continue to increase for the next 25 years and remain 14.8 per 100,000 in 2044, due to
197 the remaining hepatitis-related cancer burden and increase in alcohol-related and
198 NASH-related liver cancers. This alarming projection may imply immediate public
199 health action in China.

200 Consistent with previous studies(4, 5, 22), the incidence and mortality rates of liver
201 cancer in the current study decreased in East Asia in the past few decades. The decline
202 in liver cancer burden among East Asia areas were clearly attributed to the efforts in
203 preventing hepatitis virus infection. Japanese government launched national projects
204 for HCV blood test since 1989 and provided interferon therapy for HCV-positive
205 adults for five years since 2002(23). Consequently, the incidence of liver cancer in
206 Japan peaked in 2000-2004 and decreased thereafter(24). We also found the plateaued
207 incidence of liver cancer between 2000-2004 in this study and decreased by 78%
208 between 2004 and 2044 in Japan (**Figure 1A**). Similarly, the government of Taiwan
209 China and South Korea launched universal HBV vaccination programs in 1984 and

210 1995, respectively(24). Subsequently, HBV-related liver cancer incidence in young
211 adults was reported to decrease significantly(25). Followed these East Asia areas, the
212 government of Mainland China has issued a “blood donation law” since 1998, which
213 regulated blood donation and prevented the blood transmission of HBV. Furthermore,
214 a nationwide policy of free HBV vaccination for all newborns and children has been
215 universally implemented since 2002(26, 27). These efforts markedly reduced the HBV
216 surface antigen (HBsAg) carrier rates in Chinese populations from 10.22% to 3.59%
217 (unvaccinated vs. vaccinated population)(28, 29). Along with these effective public
218 health policies, our results showed that the hepatitis-related liver cancer burden in
219 Mainland China sharply decreased from 23.1 per 100,000 (18.6 per 100,000 for HBV;
220 6.9 per 100,000 for HCV) in 1990 to 8.6 per 100,000 (6.9 per 100,000 for HBV; 1.7
221 per 100,000 for HCV) in 2015, following what had happened in Japan, Korea, and the
222 rest of East Asia (**Table 1**).

223 However, unlike the consistently declined liver cancer burden in other East Asia areas,
224 the hepatitis-related cancer burden in Mainland China remained stable between 2015-
225 2019 and projected to increase till 2044 in our study (9.4 per 100,000 for HBV; 2.3
226 per 100,000 for HCV). As previously reported in South Korea and Taiwan China, the
227 “lag effect” might account for the elevated disease burden in Mainland China, where
228 the incidence of liver cancer among elderly hepatitis reservoirs remains high(15, 30).
229 Yue *et al.* found that the rate of elderly HCC patients increased by 55.9% in Mainland
230 China over 3 decades, related deaths increased by 39.9%, and the corresponding
231 disease burden increased by 31.4%(31). Moreover, less than one-third of Chinese
232 adults were reported to establish vaccine-mediated immunity for hepatitis virus, and
233 these high-risk people might eventually contribute to the elevated disease burden of
234 liver cancer in China(32). Taken together, it was necessary for the Chinese
235 government to implement a nationwide catch-up vaccination policy in the adult
236 population. In addition, active treatment policies for hepatitis reservoirs should also
237 be enhanced, while approximately 28 million HBV carriers and 200,000 new HCV
238 cases need treatment in Mainland China(33, 34).

239 In addition to the remaining hepatitis-related cancer burden, emerging challenges such
240 as alcohol and NASH might be responsible for the rapid increasing liver cancer
241 burden in Mainland China. In the current study, increased liver cancer burden in the
242 UK and US was widely observed, where alcohol and NASH rather than hepatitis virus
243 played major roles in contrast to East Asia(12, 35). Interestingly, the changing
244 patterns of alcohol- and NASH-related liver cancer incidence were found similar
245 among Mainland China (0.93 to 1.51 per 100,000 for alcohol; 0.5 to 0.73 per 100,000
246 for NASH) and Western countries in our projection (**Figure 1D, E**), which indicated
247 the changing etiologies of liver cancer in Mainland China(36). Over decades, the
248 alcohol consumption almost doubled from 4.1 liters to 7.2 liters per person in
249 Mainland China, and 22.7% of Chinese adults had engaged in heavy episodic
250 drinking(37). Similarly, overweight and obesity have increased rapidly in the past four

251 decades in China, with rates estimated at 11.1% for overweight and 7.9% for obesity
252 in children and adolescents(17), total liver cancer cases were estimated to increase
253 48% from 2016 to 2030, considering the emerging NAFLD- and NASH-related
254 cases(38). Consistent with the prevalence of alcohol abuse and overweight, we
255 predicted that the incidence of alcohol- and NASH-related liver cancer increase by
256 62% and 46%, respectively, in Mainland China during 2020-2044.

257 Therefore, it is vital to prevent alcohol abuse and obesity from individual and
258 government aspects. For individuals, interventions should be provided by trained staff
259 to initiate changes in risky binge drinking once individuals are screened or assessed
260 for problematic alcohol use(39). In addition, increasing alcohol taxes, the alcohol
261 policy environment, including liquor licensing laws, accessibility restrictions, and
262 minimum legal drinking age laws, should be enhanced by the government to reduce
263 alcohol use at the population level(40). Healthy diet, increased physical activity, and
264 weight loss should be encouraged for overweight individuals(41). Of importance,
265 universal education for obesity control must be provided to better inform the public in
266 Mainland China(42), in particular, promoting changes in lifestyle and diet for Chinese
267 children to help relieve the future obesity burden(43).

268 Our study is population-based and incorporates high-quality data from the GBD study,
269 which reliably collects and classifies cancer cases at the global level. Nevertheless,
270 several limitations should be noted. First, some important etiologies, such as aflatoxin
271 B1, tobacco smoking, and multi-etiological liver cancer, were not discussed due to the
272 scarcity of data in the GBD database. Second, the NOREPRED model performs
273 projection based on the assumption that trends observed in the past will continue in
274 the future, which may not be the case. In addition, data from the GBD database may
275 not be detailed enough to make precise predictions. For example, we recently found
276 an overall decline in the disease burden of hepatocellular carcinoma in the US
277 population using the SEER database, in contrast to the currently increasing trends(44);
278 besides, An *et al.* observed the overall decline in HCC incidence among Chinese
279 population from national database(16), thus, our findings must be interpreted with
280 caution. Third, GBD studies provide metrics rather than original data; however, the
281 GBD database is an unparalleled resource for the overall prediction and comparison
282 of disease trends among countries and regions. Although the prediction should be
283 reexamined comprehensively using more detailed and original data from the national
284 registry of China, the possible resurgence of liver cancer burden found in our study is
285 alarming. Previous studies have predicted that the disease burden will continue to
286 decline in Mainland China(45). Our timely prediction is important in urging the
287 Chinese society to rethink and take action to prevent the emerging resurgence of the
288 liver cancer burden.

289

290 **Conclusion**

291 Unexpectedly, the current study predicted that the declined liver cancer burden in
292 Mainland China will reverse and increase again through 2044, due to remaining
293 hepatitis-related cancer burden and changing prevalence of alcohol and NASH in
294 Mainland China. The increasing trend we predict requires vigilance from the public
295 health care providers and policymakers in China and calls for enhanced prevention
296 and treatment of hepatitis reservoirs. Besides, we specifically propose the
297 encouragement of enhanced lifestyle modifications, such as drinking cessation and
298 obesity prevention, especially for the younger generation in Mainland China. Our
299 analyses are informative and may guide further action for control the liver cancer
300 burden in Mainland China.

301

302 **Abbreviations:** ASDR: age-standardized disability-adjusted life-years rate; ALD:
303 alcoholic liver disease; ASIR: age-standardized incidence rate; ASMR: age-
304 standardized mortality rate; DAA: Direct-acting antiviral; DALYS: disability-adjusted
305 life-years; GBD: the Global Burden of Disease study; HBV: Hepatitis B virus; HBsAg:
306 Hepatitis B virus surface antigen; HCV: Hepatitis C virus; NAFLD: nonalcoholic
307 fatty liver disease; NASH: nonalcoholic steatohepatitis; UK: the United Kingdom; US:
308 the United States of America.

309

310 **Acknowledgement**

311 We sincerely thank the work performed by the Global Burden of Disease Study 2019
312 collaborators for providing this invaluable database.

313

314 **Ethical approval statement**

315 Ethical approval and consent were not required as this study was based on publicly
316 available data.

317

318 **Patient consent**

319 Patient consents were not required in accordance with local institution guidelines
320 because the study is a retrospective database research in nature, there was no direct
321 patient contact. Institutional Review Board approval was not required according to
322 our institution policy.

323

324 **Author contribution**

325 ZF and LZ: guarantor of the article. ZF, LZ, JH, TT and CC: conception/design. JH,

326 CC, TT, and WL: collection and/or assembly of data. JH, CC, TT, and RC: data
327 analysis and interpretation. JH, CC, RC, SL, HD and TJ: manuscript writing. JH, CC,
328 TT, WL, RC, SL, HD, TJ, and ZF: final approval of manuscript. The work reported in
329 the paper has been performed by the authors, unless clearly specified in the text.

330

331 **Declaration of interest**

332 The authors declare that the research was conducted in the absence of any commercial
333 or financial relationships that could be construed as a potential conflict of interest.

334

335 **Funding information**

336 This study was partially supported by the National Natural Science Foundation of
337 China [grants 81773555], the funders had no role in the design of the study or the
338 interpretation of the findings.

339

340 **Data sharing statement**

341 The datasets generated for this study are available on request to the corresponding
342 author (Davidfuzming@whu.edu.cn).

343 **References**

- 344 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.
345 Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
346 Worldwide for 36 Cancers in 185 Countries. **CA Cancer J Clin** 2021;71:209-
347 249;10.3322/caac.21660.
- 348 2. Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen
349 W. Cancer statistics in China and United States, 2022: profiles, trends, and
350 determinants. **Chin Med J (Engl)** 2022;135:584-
351 590;10.1097/CM9.0000000000002108.
- 352 3. Global Burden of Disease Cancer Collaboration. Global, Regional, and National
353 Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and
354 Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic
355 Analysis for the Global Burden of Disease Study. **JAMA Oncol** 2017;3:524-
356 548;10.1001/jamaoncol.2016.5688.
- 357 4. Bai L, Liu Z, Fang Q, Yan Q, Shi O, Bao P, Mu L, Chen X, Zhang T. The trends
358 and projections in the incidence and mortality of liver cancer in urban Shanghai: a
359 population-based study from 1973 to 2020. **Clin Epidemiol** 2018;10:277-
360 288;10.2147/CLEP.S153951.
- 361 5. Wu J, Yang S, Xu K, Ding C, Zhou Y, Fu X, Li Y, Deng M, Wang C, Liu X, Li L.
362 Patterns and Trends of Liver Cancer Incidence Rates in Eastern and Southeastern
363 Asian Countries (1983-2007) and Predictions to 2030. **Gastroenterology**
364 2018;154:1719-1728 e1715;10.1053/j.gastro.2018.01.033.
- 365 6. Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary
366 Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional,
367 and National Level: Results From the Global Burden of Disease Study 2015. **JAMA**
368 **Oncol** 2017;3:1683-1691;10.1001/jamaoncol.2017.3055.
- 369 7. Fan JH, Wang JB, Jiang Y, Xiang W, Liang H, Wei WQ, Qiao YL, Boffetta P.
370 Attributable causes of liver cancer mortality and incidence in china. **Asian Pac J**
371 **Cancer Prev** 2013;14:7251-7256;10.7314/apjcp.2013.14.12.7251.
- 372 8. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular
373 Carcinoma. **Hepatology** 2021;73 Suppl 1:4-13;10.1002/hep.31288.
- 374 9. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S,
375 Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. **Nat Rev**
376 **Dis Primers** 2021;7:6;10.1038/s41572-020-00240-3.
- 377 10. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH
378 to HCC: current concepts and future challenges. **Nat Rev Gastroenterol Hepatol**
379 2019;16:411-428;10.1038/s41575-019-0145-7.

- 380 11. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM.
381 Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort
382 study. **BMJ** 2011;343:d6891;10.1136/bmj.d6891.
- 383 12. Dang K, Hirode G, Singal AK, Sundaram V, Wong RJ. Alcoholic Liver Disease
384 Epidemiology in the United States: A Retrospective Analysis of 3 US Databases. **Am**
385 **J Gastroenterol** 2020;115:96-104;10.14309/ajg.0000000000000380.
- 386 13. Liu Z, Mao X, Jiang Y, Cai N, Jin L, Zhang T, Chen X. Changing trends in the
387 disease burden of primary liver cancer caused by specific etiologies in China. **Cancer**
388 **Med** 2019;8:5787-5799;10.1002/cam4.2477.
- 389 14. Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, Hijioka T,
390 Katayama K, Yabuuchi I, Yoshihara H, Inoue A, Kato M, Takehara T, Tamura S,
391 Kasahara A, Hayashi N, Tsukuma H. Declining incidence of hepatocellular carcinoma
392 in Osaka, Japan, from 1990 to 2003. **Ann Intern Med** 2008;148:820-
393 826;10.7326/0003-4819-148-11-200806030-00004.
- 394 15. Ni YH, Chen DS. Hepatitis B vaccination in children: the Taiwan experience.
395 **Pathol Biol (Paris)** 2010;58:296-300;10.1016/j.patbio.2009.11.002.
- 396 16. An L, Zheng R, Zhang S, Chen R, Wang S, Sun K, Lu L, Zhang X, Zhao H, Zeng
397 H, Wei W, He J. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma
398 incidence between 2006 and 2015 in China: estimates based on data from 188
399 population-based cancer registries. **Hepatobiliary Surg Nutr** 2023;12:45-
400 55;10.21037/hbsn-21-75.
- 401 17. Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China.
402 **Lancet Diabetes Endocrinol** 2021;9:373-392;10.1016/S2213-8587(21)00045-0.
- 403 18. G. B. D. Disease Injury Incidence Prevalence Collaborators. Global, regional, and
404 national incidence, prevalence, and years lived with disability for 354 diseases and
405 injuries for 195 countries and territories, 1990-2017: a systematic analysis for the
406 Global Burden of Disease Study 2017. **Lancet** 2018;392:1789-1858;10.1016/S0140-
407 6736(18)32279-7.
- 408 19. G. B. D. Diseases Injuries Collaborators. Global burden of 369 diseases and
409 injuries in 204 countries and territories, 1990-2019: a systematic analysis for the
410 Global Burden of Disease Study 2019. **Lancet** 2020;396:1204-1222;10.1016/S0140-
411 6736(20)30925-9.
- 412 20. Moller B, Fekjaer H, Hakulinen T, Sigvaldason H, Storm HH, Talback M,
413 Haldorsen T. Prediction of cancer incidence in the Nordic countries: empirical
414 comparison of different approaches. **Stat Med** 2003;22:2751-2766;10.1002/sim.1481.
- 415 21. Araghi M, Soerjomataram I, Jenkins M, Brierley J, Morris E, Bray F, Arnold M.
416 Global trends in colorectal cancer mortality: projections to the year 2035.

- 417 **International Journal of Cancer** 2019;144:2992-3000;10.1002/ijc.32055.
- 418 22. Katanoda K, Ito Y, Sobue T. International comparison of trends in cancer
419 mortality: Japan has fallen behind in screening-related cancers. **Jpn J Clin Oncol**
420 2021;51:1680-1686;10.1093/jjco/hyab139.
- 421 23. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets
422 West. **J Gastroenterol Hepatol** 2009;24:336-345;10.1111/j.1440-1746.2009.05789.x.
- 423 24. Tsukuma H, Tanaka H, Ajiki W, Oshima A. Liver cancer and its prevention.
424 **Asian Pac J Cancer Prev** 2005;6:244-250
- 425 25. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY,
426 Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of
427 hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. **N**
428 **Engl J Med** 1997;336:1855-1859;10.1056/NEJM199706263362602.
- 429 26. Jia Y, Li L, Cui F, Zhang D, Zhang G, Wang F, Gong X, Zheng H, Wu Z, Miao N,
430 Sun X, Zhang L, Lv J, Yang F. Cost-effectiveness analysis of a hepatitis B vaccination
431 catch-up program among children in Shandong Province, China. **Hum Vaccin**
432 **Immunother** 2014;10:2983-2991;10.4161/hv.29944.
- 433 27. Zhang Q, Qi W, Wang X, Zhang Y, Xu Y, Qin S, Zhao P, Guo H, Jiao J, Zhou C,
434 Ji S, Wang J. Epidemiology of Hepatitis B and Hepatitis C Infections and Benefits of
435 Programs for Hepatitis Prevention in Northeastern China: A Cross-Sectional Study.
436 **Clin Infect Dis** 2016;62:305-312;10.1093/cid/civ859.
- 437 28. Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on
438 hepatitis B virus infections in China over a 20-year period. **Int J Infect Dis**
439 2012;16:e82-88;10.1016/j.ijid.2011.10.009.
- 440 29. Huang P, Zhu LG, Zhu YF, Yue M, Su J, Zhu FC, Yang HT, Zhang Y, Shen HB,
441 Yu RB, Zhai XJ, Peng ZH. Seroepidemiology of hepatitis B virus infection and
442 impact of vaccination. **World J Gastroenterol** 2015;21:7842-
443 7850;10.3748/wjg.v21.i25.7842.
- 444 30. Kim BH, Park JW. Epidemiology of liver cancer in South Korea. **Clin Mol**
445 **Hepatol** 2018;24:1-9;10.3350/cmh.2017.0112.
- 446 31. Yue T, Xu M, Cai T, Zhu H, Pourkarim MR, De Clercq E, Li G. Gender disparity
447 and temporal trend of liver cancer in China from 1990 to 2019 and predictions in a
448 25-year period. **Front Public Health** 2022;10:956712;10.3389/fpubh.2022.956712.
- 449 32. Bai X, Chen L, Liu X, Tong Y, Wang L, Zhou M, Li Y, Hu G. Adult Hepatitis B
450 Virus Vaccination Coverage in China from 2011 to 2021: A Systematic Review.
451 **Vaccines (Basel)** 2022;10;10.3390/vaccines10060900.
- 452 33. Xia R, Peng J, He J, Jiang P, Yuan C, Liu X, Yao Y. The Serious Challenge of

- 453 Occult Hepatitis B Virus Infection-Related Hepatocellular Carcinoma in China. **Front**
454 **Microbiol** 2022;13:840825;10.3389/fmicb.2022.840825.
- 455 34. Mei X, Lu H. Prevalence, diagnosis, and treatment of hepatitis C in Mainland
456 China. **Glob Health Med** 2021;3:270-275;10.35772/ghm.2021.01080.
- 457 35. Brown KF, Rungay H, Dunlop C, Ryan M, Quartly F, Cox A, Deas A, Elliss-
458 Brookes L, Gavin A, Hounscome L, Huws D, Ormiston-Smith N, Shelton J, White C,
459 Parkin DM. The fraction of cancer attributable to modifiable risk factors in England,
460 Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. **Br J Cancer**
461 2018;118:1130-1141;10.1038/s41416-018-0029-6.
- 462 36. Im PK, Millwood IY, Kartsonaki C, Guo Y, Chen Y, Turnbull I, Yu C, Du H, Pei P,
463 Lv J, Walters RG, Li L, Yang L, Chen Z, China Kadoorie Biobank collaborative g.
464 Alcohol drinking and risks of liver cancer and non-neoplastic chronic liver diseases in
465 China: a 10-year prospective study of 0.5 million adults. **BMC Med**
466 2021;19:216;10.1186/s12916-021-02079-1.
- 467 37. Hu A, Jiang H, Dowling R, Guo L, Zhao X, Hao W, Xiang X. The transition of
468 alcohol control in China 1990-2019: Impacts and recommendations. **Int J Drug**
469 **Policy** 2022;105:103698;10.1016/j.drugpo.2022.103698.
- 470 38. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J,
471 Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC,
472 Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S,
473 Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J,
474 Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China,
475 France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the
476 period 2016-2030. **J Hepatol** 2018;69:896-904;10.1016/j.jhep.2018.05.036.
- 477 39. Kuntsche E, Kuntsche S, Thrul J, Gmel G. Binge drinking: Health impact,
478 prevalence, correlates and interventions. **Psychol Health** 2017;32:976-
479 1017;10.1080/08870446.2017.1325889.
- 480 40. Balodis IM, Potenza MN, Olmstead MC. Binge drinking in undergraduates:
481 relationships with sex, drinking behaviors, impulsivity, and the perceived effects of
482 alcohol. **Behav Pharmacol** 2009;20:518-526;10.1097/FBP.0b013e328330c779.
- 483 41. Fan JG, Wei L, Zhuang H, National Workshop on Fatty L, Alcoholic Liver
484 Disease CSoHCMA, Fatty Liver Disease Expert Committee CMDA. Guidelines of
485 prevention and treatment of nonalcoholic fatty liver disease (2018, China). **J Dig Dis**
486 2019;20:163-173;10.1111/1751-2980.12685.
- 487 42. The Lancet Diabetes Endocrinology. Obesity in China: time to act. **Lancet**
488 **Diabetes Endocrinol** 2021;9:407;10.1016/S2213-8587(21)00150-9.
- 489 43. Chen J, Jin L, Wang F, Huang K, Wu W, Chen R, Maimaiti M, Chen S, Cao B,

490 Zhu M, Wang C, Su Z, Liang Y, Yao H, Wei H, Zheng R, Du H, Luo F, Li P, Yu Y,
491 Wang E, Dorazio RM, Fu J. Risk factors for obesity and overweight in Chinese
492 children: a nationwide survey. **Obesity (Silver Spring)** 2022;30:1842-
493 1850;10.1002/oby.23515.

494 44. Han J, Wang B, Liu W, Wang S, Chen R, Chen M, Fu Z. Declining disease
495 burden of HCC in the United States, 1992-2017: A population-based analysis.
496 **Hepatology** 2022;76:576-588;10.1002/hep.32355.

497 45. Yue T, Zhang Q, Cai T, Xu M, Zhu H, Pourkarim MR, De Clercq E, Li G. Trends
498 in the disease burden of HBV and HCV infection in China from 1990-2019. **Int J**
499 **Infect Dis** 2022;122:476-485;10.1016/j.ijid.2022.06.017.

500

Table 1. Disease burden of liver cancer from GBD by etiologies, 1990-2044.

| Period | Mainland China | | | Taiwan China | | | Japan | | | Republic of Korea | | | United Kingdom | | | United States of America | | |
|------------|----------------|-------|--------|--------------|-------|--------|-------|-------|--------|-------------------|-------|--------|----------------|------|-------|--------------------------|------|--------|
| | ASIR | ASMR | ASDR | ASIR | ASMR | ASDR | ASIR | ASMR | ASDR | ASIR | ASMR | ASDR | ASIR | ASMR | ASDR | ASIR | ASMR | ASDR |
| All causes | | | | | | | | | | | | | | | | | | |
| 1990-1994 | 28.1 | 27.49 | 845.3 | 12.83 | 12.65 | 373.88 | 16.16 | 12.22 | 312.74 | 9.14 | 9.24 | 263.76 | 2.01 | 1.81 | 44.38 | 2.36 | 2.06 | 54.23 |
| 1995-1999 | 27.63 | 27.63 | 839.76 | 15.81 | 12.21 | 347.64 | 18.94 | 15.25 | 370.6 | 14.34 | 12.28 | 349.67 | 2.26 | 1.98 | 48.34 | 2.93 | 2.47 | 65.04 |
| 2000-2004 | 19.07 | 17.17 | 507.85 | 19.26 | 12.72 | 343.03 | 23.63 | 14.07 | 324.66 | 25.99 | 23.75 | 669.45 | 2.8 | 2.35 | 56.44 | 3.51 | 2.89 | 76.32 |
| 2005-2009 | 10.23 | 9.89 | 284.41 | 17.1 | 13.25 | 345.99 | 16.29 | 11.71 | 258.2 | 26.05 | 20.31 | 552.93 | 3.56 | 2.91 | 69.25 | 4.1 | 3.36 | 88.85 |
| 2010-2014 | 9.93 | 8.87 | 252.97 | 9.04 | 7.23 | 181.28 | 13.53 | 9.35 | 198.1 | 23.74 | 17.49 | 456.51 | 4.37 | 3.48 | 80.63 | 4.58 | 3.69 | 96.32 |
| 2015-2019 | 10.64 | 9.65 | 276.52 | 8.07 | 6.72 | 168.4 | 11.44 | 7.88 | 162.55 | 22.2 | 15.71 | 400.04 | 4.82 | 3.74 | 86.45 | 4.94 | 4.01 | 103.95 |
| 2020-2024 | 11.54 | 10.6 | 308.92 | 7.11 | 6.15 | 155.24 | 9.45 | 6.66 | 136.28 | 20.4 | 13.82 | 345.28 | 5.27 | 3.98 | 91.81 | 5.23 | 4.27 | 109.21 |
| 2025-2029 | 12.43 | 11.53 | 338.64 | 6.53 | 5.8 | 146.62 | 7.7 | 5.66 | 117.6 | 18.92 | 12.44 | 305.04 | 5.52 | 4.08 | 94.67 | 5.36 | 4.4 | 111.16 |
| 2030-2034 | 13.32 | 12.47 | 365.61 | 5.98 | 5.37 | 138.49 | 6.34 | 5.01 | 106.45 | 17.38 | 11.14 | 273.04 | 5.6 | 4.07 | 95.23 | 5.34 | 4.39 | 109.91 |
| 2035-2039 | 13.98 | 13.16 | 384.04 | 5.73 | 5.15 | 133.94 | 5.56 | 4.87 | 103.92 | 16.2 | 10.29 | 252.61 | 5.5 | 3.94 | 93.47 | 5.21 | 4.27 | 106.51 |
| 2040-2044 | 14.78 | 14.02 | 404.56 | 5.58 | 5.01 | 131.87 | 4.84 | 4.69 | 102.15 | 15.18 | 9.53 | 235.3 | 5.42 | 3.83 | 92.15 | 5.07 | 4.14 | 103.55 |
| Alcohol | | | | | | | | | | | | | | | | | | |
| 1990-1994 | 2.1 | 2.08 | 58.98 | 1.26 | 1.28 | 34.96 | 2.04 | 1.54 | 40.89 | 1.19 | 1.23 | 32.14 | 0.73 | 0.65 | 16.02 | 0.7 | 0.61 | 15.81 |
| 1995-1999 | 2.04 | 2.06 | 57.2 | 1.6 | 1.24 | 33.52 | 2.3 | 1.84 | 46.8 | 1.9 | 1.65 | 43.46 | 0.84 | 0.72 | 17.82 | 0.86 | 0.72 | 19.02 |
| 2000-2004 | 1.41 | 1.3 | 34.95 | 1.95 | 1.3 | 33.78 | 2.23 | 1.65 | 40.34 | 3.59 | 3.33 | 86.83 | 1.07 | 0.88 | 21.36 | 1.02 | 0.82 | 22.21 |
| 2005-2009 | 0.79 | 0.78 | 20.31 | 1.67 | 1.3 | 33.03 | 1.93 | 1.36 | 31.94 | 3.73 | 2.99 | 75.18 | 1.36 | 1.09 | 26.2 | 1.2 | 0.96 | 26 |
| 2010-2014 | 0.8 | 0.73 | 18.87 | 0.81 | 0.66 | 16.18 | 1.61 | 1.07 | 24.58 | 3.54 | 2.68 | 64.93 | 1.65 | 1.27 | 29.97 | 1.35 | 1.06 | 28.49 |
| 2015-2019 | 0.93 | 0.62 | 22.25 | 0.72 | 0.6 | 14.78 | 1.31 | 0.87 | 19.73 | 3.48 | 2.52 | 60.07 | 1.79 | 1.35 | 31.67 | 1.55 | 1.23 | 32.46 |
| 2020-2024 | 1.08 | 0.55 | 26.34 | 0.63 | 0.55 | 13.45 | 1.1 | 0.72 | 16.16 | 3.37 | 2.33 | 54.85 | 1.93 | 1.42 | 33.14 | 1.74 | 1.39 | 35.89 |

| | | | | | | | | | | | | | | | | | | |
|-----------|------|------|-------|------|------|-------|------|------|-------|------|------|-------|------|------|-------|------|------|-------|
| 2025-2029 | 1.21 | 0.5 | 30.18 | 0.57 | 0.52 | 12.71 | 0.94 | 0.61 | 13.77 | 3.25 | 2.18 | 50.58 | 2 | 1.44 | 33.71 | 1.85 | 1.48 | 37.73 |
| 2030-2034 | 1.33 | 0.5 | 33.61 | 0.53 | 0.5 | 12.24 | 0.84 | 0.55 | 12.4 | 3.07 | 1.99 | 46.54 | 2.01 | 1.42 | 33.52 | 1.88 | 1.5 | 37.92 |
| 2035-2039 | 1.41 | 0.51 | 35.88 | 0.52 | 0.49 | 12.15 | 0.8 | 0.53 | 12.05 | 2.9 | 1.86 | 43.54 | 1.95 | 1.37 | 32.62 | 1.84 | 1.46 | 36.87 |
| 2040-2044 | 1.51 | 0.53 | 38.54 | 0.51 | 0.48 | 12.36 | 0.77 | 0.53 | 11.92 | 2.75 | 1.74 | 41.04 | 1.91 | 1.33 | 31.87 | 1.8 | 1.43 | 36.05 |

HBV

| | | | | | | | | | | | | | | | | | | |
|-----------|-------|-------|--------|------|------|--------|------|------|-------|-------|-------|--------|------|------|-------|------|------|-------|
| 1990-1994 | 18.63 | 17.81 | 588.81 | 7.01 | 6.72 | 219.66 | 2.51 | 1.82 | 56.18 | 5.77 | 5.68 | 177.81 | 0.32 | 0.26 | 7.86 | 0.35 | 0.29 | 8.92 |
| 1995-1999 | 18.45 | 18.08 | 588.06 | 7.89 | 5.93 | 190.56 | 2.31 | 2.13 | 62.64 | 9.08 | 7.56 | 235.63 | 0.35 | 0.28 | 8.52 | 0.43 | 0.34 | 10.56 |
| 2000-2004 | 12.75 | 11.19 | 355.65 | 8.94 | 5.61 | 174.67 | 2.62 | 1.85 | 52.56 | 16.52 | 14.72 | 451.23 | 0.43 | 0.33 | 9.82 | 0.52 | 0.4 | 12.31 |
| 2005-2009 | 6.71 | 6.32 | 197 | 7.7 | 5.68 | 172.9 | 2.25 | 1.49 | 41.05 | 16.41 | 12.36 | 367.12 | 0.55 | 0.41 | 12.12 | 0.6 | 0.45 | 13.86 |
| 2010-2014 | 6.49 | 5.65 | 174.89 | 3.92 | 2.97 | 87.75 | 1.86 | 1.17 | 31.22 | 14.53 | 10.35 | 297.62 | 0.68 | 0.48 | 14.02 | 0.64 | 0.48 | 14.36 |
| 2015-2019 | 6.86 | 6.03 | 188.89 | 3.65 | 2.89 | 85.05 | 1.49 | 0.94 | 24.67 | 13.18 | 9.01 | 254.84 | 0.75 | 0.52 | 15.23 | 0.69 | 0.52 | 15.54 |
| 2020-2024 | 7.43 | 6.59 | 210.38 | 3.36 | 2.79 | 82.25 | 1.16 | 0.75 | 19.72 | 11.83 | 7.71 | 215.08 | 0.83 | 0.55 | 16.38 | 0.73 | 0.55 | 16.31 |
| 2025-2029 | 7.98 | 7.13 | 230.09 | 3.2 | 2.75 | 80.43 | 0.94 | 0.62 | 16.46 | 10.74 | 6.77 | 186.44 | 0.89 | 0.57 | 17.18 | 0.75 | 0.56 | 16.71 |
| 2030-2034 | 8.54 | 7.69 | 247.7 | 3.05 | 2.67 | 78.43 | 0.79 | 0.53 | 14.52 | 9.79 | 5.99 | 165.46 | 0.92 | 0.58 | 17.6 | 0.75 | 0.56 | 16.68 |
| 2035-2039 | 8.95 | 8.1 | 259.64 | 2.98 | 2.63 | 77.12 | 0.71 | 0.51 | 13.8 | 9.11 | 5.5 | 152.65 | 0.92 | 0.56 | 17.61 | 0.73 | 0.54 | 16.34 |
| 2040-2044 | 9.43 | 8.59 | 272.49 | 2.96 | 2.63 | 77.2 | 0.65 | 0.48 | 13.23 | 8.54 | 5.08 | 142.13 | 0.93 | 0.55 | 17.68 | 0.72 | 0.53 | 16.1 |

HCV

| | | | | | | | | | | | | | | | | | | |
|-----------|------|------|--------|------|------|-------|-------|-------|--------|------|------|-------|------|------|-------|------|------|-------|
| 1990-1994 | 4.51 | 4.78 | 109.09 | 3.24 | 3.39 | 81.09 | 10.45 | 8 | 192.61 | 1.41 | 1.55 | 33.18 | 0.69 | 0.67 | 14.06 | 0.83 | 0.76 | 17.9 |
| 1995-1999 | 4.34 | 4.68 | 105.88 | 4.56 | 3.7 | 85.05 | 12.48 | 10.19 | 233.55 | 2.19 | 2.03 | 43.51 | 0.77 | 0.73 | 15.08 | 1.05 | 0.94 | 22.06 |
| 2000-2004 | 2.98 | 2.93 | 64.44 | 6.12 | 4.33 | 94.17 | 12.46 | 9.54 | 207.07 | 3.82 | 3.76 | 82.19 | 0.94 | 0.85 | 17.34 | 1.27 | 1.1 | 26.23 |
| 2005-2009 | 1.68 | 1.77 | 37.54 | 5.67 | 4.69 | 98.55 | 10.9 | 8.02 | 165.34 | 3.85 | 3.3 | 69.61 | 1.19 | 1.06 | 21.35 | 1.5 | 1.3 | 31.06 |
| 2010-2014 | 1.6 | 1.56 | 32.49 | 3.1 | 2.67 | 53.11 | 9.02 | 6.41 | 126.34 | 3.72 | 2.98 | 59.56 | 1.49 | 1.3 | 25.54 | 1.71 | 1.44 | 34.56 |
| 2015-2019 | 1.7 | 1.71 | 35.54 | 2.66 | 2.37 | 46.77 | 7.77 | 5.49 | 105.17 | 3.63 | 2.81 | 53.96 | 1.65 | 1.4 | 27.68 | 1.77 | 1.51 | 35.81 |

| | | | | | | | | | | | | | | | | | | |
|-------------|------|------|-------|------|------|-------|------|------|-------|------|------|-------|------|------|-------|------|------|-------|
| 2020-2024 | 1.79 | 1.84 | 38.94 | 2.23 | 2.06 | 40.51 | 6.86 | 4.72 | 89.73 | 3.43 | 2.53 | 47.76 | 1.82 | 1.5 | 29.56 | 1.8 | 1.55 | 36.19 |
| 2025-2029 | 1.91 | 1.99 | 42.56 | 1.99 | 1.87 | 36.64 | 6.04 | 4.06 | 78.76 | 3.27 | 2.36 | 43.4 | 1.9 | 1.54 | 30.51 | 1.78 | 1.55 | 35.7 |
| 2030-2034 | 2.05 | 2.17 | 46.46 | 1.75 | 1.66 | 33.38 | 5.49 | 3.63 | 72.75 | 3.03 | 2.14 | 39.36 | 1.92 | 1.54 | 30.61 | 1.73 | 1.51 | 34.55 |
| 2035-2039 | 2.17 | 2.32 | 49.73 | 1.67 | 1.58 | 32.16 | 5.41 | 3.56 | 72.71 | 2.84 | 2.02 | 36.88 | 1.88 | 1.49 | 29.81 | 1.67 | 1.46 | 33.08 |
| 2040-2044 | 2.34 | 2.53 | 53.74 | 1.59 | 1.51 | 31.8 | 5.31 | 3.45 | 73.35 | 2.68 | 1.91 | 34.78 | 1.85 | 1.46 | 29.08 | 1.6 | 1.4 | 31.72 |
| NASH | | | | | | | | | | | | | | | | | | |
| 1990-1994 | 1.06 | 1.07 | 29.23 | 0.66 | 0.66 | 17.93 | 0.63 | 0.48 | 11.54 | 0.44 | 0.46 | 10.71 | 0.12 | 0.11 | 2.53 | 0.21 | 0.19 | 4.41 |
| 1995-1999 | 1.06 | 1.09 | 29.49 | 0.93 | 0.72 | 18.69 | 0.78 | 0.63 | 14.27 | 0.69 | 0.62 | 14.44 | 0.14 | 0.13 | 2.88 | 0.26 | 0.24 | 5.35 |
| 2000-2004 | 0.76 | 0.71 | 18.39 | 1.23 | 0.82 | 20.27 | 0.8 | 0.61 | 13.11 | 1.2 | 1.16 | 27.16 | 0.18 | 0.16 | 3.44 | 0.32 | 0.28 | 6.49 |
| 2005-2009 | 0.42 | 0.42 | 10.51 | 1.16 | 0.92 | 21.89 | 0.7 | 0.51 | 10.47 | 1.22 | 1.02 | 22.81 | 0.23 | 0.2 | 4.33 | 0.38 | 0.34 | 7.84 |
| 2010-2014 | 0.43 | 0.41 | 9.86 | 0.7 | 0.56 | 12.76 | 0.6 | 0.42 | 8.33 | 1.17 | 0.91 | 19.38 | 0.29 | 0.25 | 5.19 | 0.43 | 0.37 | 8.58 |
| 2015-2019 | 0.5 | 0.48 | 11.54 | 0.62 | 0.52 | 11.66 | 0.49 | 0.35 | 6.66 | 1.15 | 0.86 | 17.85 | 0.33 | 0.27 | 5.67 | 0.47 | 0.41 | 9.4 |
| 2020-2024 | 0.57 | 0.55 | 13.45 | 0.53 | 0.47 | 10.48 | 0.42 | 0.29 | 5.46 | 1.1 | 0.79 | 16.12 | 0.36 | 0.29 | 6.11 | 0.51 | 0.44 | 10.1 |
| 2025-2029 | 0.62 | 0.62 | 15.07 | 0.48 | 0.43 | 9.71 | 0.35 | 0.24 | 4.64 | 1.05 | 0.74 | 14.82 | 0.38 | 0.29 | 6.37 | 0.53 | 0.47 | 10.5 |
| 2030-2034 | 0.67 | 0.67 | 16.39 | 0.44 | 0.39 | 9 | 0.31 | 0.21 | 4.16 | 0.98 | 0.68 | 13.59 | 0.39 | 0.3 | 6.46 | 0.54 | 0.47 | 10.54 |
| 2035-2039 | 0.7 | 0.7 | 17.12 | 0.42 | 0.36 | 8.64 | 0.3 | 0.21 | 4.06 | 0.93 | 0.64 | 12.76 | 0.38 | 0.29 | 6.36 | 0.53 | 0.47 | 10.29 |
| 2040-2044 | 0.73 | 0.74 | 18.04 | 0.41 | 0.34 | 8.45 | 0.29 | 0.2 | 4 | 0.88 | 0.61 | 12.01 | 0.38 | 0.28 | 6.29 | 0.52 | 0.46 | 10.03 |

Abbreviation: GBD: Global Burden of Disease; HBV: hepatitis B virus; HCV: hepatitis C virus; NASH: non-alcoholic steatohepatitis; DALYs: Disability Adjusted Life Years

Table 2. Trends in disease burden of liver cancer from GBD by etiologies, 1990-2044.

| Country | Incidence | | | | Mortality | | | | DALYS | | | |
|--------------------------|-----------|------------------------|-----------|------------------------|-----------|----------------------------|-----------|----------------------------|-----------|----------------------------|-----------|----------------------------|
| | Trend1 | Relative change in ASR | Trend2 | Relative change in ASR | Trend1 | Relative change in ASR (%) | Trend2 | Relative change in ASR (%) | Trend1 | Relative change in ASR (%) | Trend2 | Relative change in ASR (%) |
| All causes | | | | | | | | | | | | |
| Mainland China | 1990-2009 | -0.64 | 2009-2044 | 0.44 | 1990-2009 | -0.64 | 2009-2044 | 0.42 | 1990-2009 | -0.66 | 2009-2044 | 0.42 |
| Taiwan China | 1990-2009 | 0.33 | 2009-2044 | -0.67 | 1990-2009 | -0.91 | 2009-2044 | -0.62 | 1990-2009 | -0.074 | 2009-2044 | -0.98 |
| Japan | 1990-2004 | 0.46 | 2004-2044 | -0.78 | 1990-1999 | 0.24 | 1999-2044 | -0.60 | 1990-1999 | -0.17 | 1999-2044 | -0.99 |
| Republic of Korea | 1990-2004 | 1.84 | 2004-2044 | -0.39 | 1990-2004 | 1.57 | 2004-2044 | -0.73 | 1990-2004 | 1.54 | 2004-2044 | -0.64 |
| United Kingdom | 1990-2044 | 1.69 | - | | 1990-2044 | 2,50 | - | | 1990-2044 | 1.08 | - | |
| United States of America | 1990-2044 | 1.15 | - | | 1990-2044 | 1.00 | - | | 1990-2044 | 0.91 | - | |
| Alcohol | | | | | | | | | | | | |
| Mainland China | 1990-2009 | -0.62 | 2009-2044 | 0.07 | 1990-2009 | -0.63 | 2009-2044 | -0.32 | 1990-2009 | -0.66 | 2009-2044 | 0.89 |
| Taiwan China | 1990-2009 | 0.33 | 2009-2044 | -0.69 | 1990-2009 | 0.016 | 2009-2044 | -0.63 | 1990-2009 | -0.06 | 2009-2044 | -0.63 |
| Japan | 1990-2004 | 0.093 | 2004-2044 | -0.65 | 1990-1999 | 0.21 | 1999-2044 | -0.71 | 1990-1999 | 0.14 | 1999-2044 | -0.75 |
| Republic of Korea | 1990-2004 | 2.02 | 2004-2044 | -0.23 | 1990-2004 | 1.7 | 2004-2044 | -0.48 | 1990-2004 | 1.7 | 2004-2044 | -0.53 |
| United Kingdom | 1990-2044 | 1.62 | - | | 1990-2019 | 1.07 | 2019-2044 | -0.01 | 1990-2019 | 0.98 | 2019-2044 | 0.006 |
| United States of America | 1990-2044 | 1.04 | - | | 1990-2044 | 1.34 | - | | 1990-2029 | 1.4 | 2029-2044 | -0.044 |
| HBV | | | | | | | | | | | | |
| Mainland China | 1990-2009 | -0.64 | 2009-2044 | 0.41 | 1990-2009 | -0.65 | 2009-2044 | 0.36 | 1990-2009 | -0.67 | 2009-2044 | 0.38 |
| Taiwan China | 1990-2009 | 0.098 | 2009-2044 | -0.62 | 1990-2009 | -0.15 | 2009-2044 | -0.54 | 1990-2009 | -0.21 | 2009-2044 | -0.55 |

| | | | | | | | | | | | | |
|--------------------------|-----------|-------|-----------|-------|-----------|-------|-----------|-------|-----------|-------|-----------|-------|
| Japan | 1990-2044 | -0.65 | - | | 1990-2044 | -0.74 | - | | 1990-2044 | -0.76 | - | |
| Republic of Korea | 1990-2004 | 1.86 | 2004-2044 | -0.48 | 1990-2004 | 1.59 | 2004-2044 | -0.65 | 1990-2004 | 1.54 | 2004-2044 | -0.69 |
| United Kingdom | 1990-2044 | 1.91 | - | | 1990-2044 | 0.72 | - | | 1990-2044 | 1.25 | - | |
| United States of America | 1990-2044 | 1.06 | - | | 1990-2044 | 0.83 | - | | 1990-2044 | 0.80 | - | |
| HCV | | | | | | | | | | | | |
| Mainland China | 1990-2009 | -0.63 | 2009-2044 | 0.39 | 1990-2009 | -0.63 | 2009-2044 | 0.43 | 1990-2009 | -0.66 | 2009-2044 | 0.43 |
| Taiwan China | 1990-2009 | 0.75 | 2009-2044 | -0.72 | 1990-2009 | 0.75 | 2009-2044 | -0.68 | 1990-2009 | 0.22 | 2009-2044 | -0.68 |
| Japan | 1990-1999 | 0.19 | 1999-2044 | -0.57 | 1990-1999 | 0.27 | 1999-2044 | -0.66 | 1990-1999 | 0.21 | 1999-2044 | -0.69 |
| Republic of Korea | 1990-2004 | 1.71 | 2004-2044 | -0.29 | 1990-2004 | 1.42 | 2004-2044 | -0.49 | 1990-2004 | 1.48 | 2004-2044 | -0.58 |
| United Kingdom | 1990-2044 | 1.68 | - | | 1990-2019 | 1.08 | 2019-2044 | 0.04 | 1990-2019 | 0.97 | 2019-2044 | 0.05 |
| United States of America | 1990-2044 | 0.93 | - | | 1990-2044 | 0.84 | - | | 1990-2044 | 0.77 | - | |
| NASH | | | | | | | | | | | | |
| Mainland China | 1990-2009 | -0.60 | 2009-2044 | 0.74 | 1990-2009 | -0.61 | 2009-2044 | 0.76 | 1990-2009 | -0.64 | 2009-2044 | 0.72 |
| Taiwan China | 1990-2009 | 0.40 | 2009-2044 | -0.65 | 1990-2009 | 0.39 | 2009-2044 | -0.63 | 1990-2009 | 0.22 | 2009-2044 | -0.61 |
| Japan | 1990-2004 | 0.27 | 2004-2044 | 0.63 | 1990-1999 | 0.31 | 1999-2044 | -0.68 | 1990-1999 | 0.24 | 1999-2044 | -0.72 |
| Republic of Korea | 1990-2004 | 1.73 | 2004-2044 | -0.27 | 1990-2004 | 1.5 | 2004-2044 | -0.47 | 1990-2004 | 1.5 | 2004-2044 | -0.56 |
| United Kingdom | 1990-2044 | 2.2 | - | | 1990-2019 | 1.45 | 2019-2044 | 0.03 | 1990-2019 | 1.24 | 2019-2044 | 0.11 |
| United States of America | 1990-2044 | 1.47 | - | | 1990-2044 | 1.42 | - | | 1990-2019 | 1.14 | 2019-2044 | 0.06 |

Abbreviation: GBD: Global Burden of Disease; HBV: hepatitis B virus; HCV: hepatitis C virus; NASH: non-alcoholic steatohepatitis; DALYs: Disability Adjusted Life Years


Figure legends

Figure 1. Trends in liver cancer incidence through 1990 to 2045: observed (solid lines) and predicted rates (dashed lines). Age-standardized to world population per 100,000.


Figure 2. Trends in liver cancer mortality through 1990 to 2045: observed (solid lines) and predicted rates (dashed lines). Age-standardized to world population per 100,000.

Figure 3. Trends in liver cancer DALYS through 1990 to 2045: observed (solid lines) and predicted rates (dashed lines). Age-standardized to world population per 100,000.


DALYS: Disability Adjusted Life Years.




A. All Causes




B. HBV




C. HCV




D. Alcohol




E. NASH




A. All Causes




B. HBV




C. HCV




D. Alcohol




E. NASH




A. All Causes




B. HBV



C. HCV



D. Alcohol



E. NASH